| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
trans-Vaccenic acid targets key proteins in the apoptosis pathway, particularly by inhibiting the phosphorylation of Akt and Bad. This inhibition leads to the induction of apoptosis in cancer cells. It is also an endogenous metabolite, serving as a precursor for the synthesis of the conjugated linoleic acid (CLA) isomer cis-9, trans-11 C18:2, which is an abundant CLA isomer in meat and milk. Its effects on metabolic syndrome are linked to the remodeling of adipose tissue and attenuation of ectopic lipid accumulation.
|
|---|---|
| ln Vitro |
In vitro, trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell viability in a dose-dependent manner at concentrations ranging from 0 to 200 µM. It induces apoptosis in NPC cells at concentrations of 25-100 µM. This effect is mediated through the inactivation of Akt and Bad, leading to increased levels of cleaved PARP and cleaved caspase-3. It is reduced in the rumen to form stearic acid or desaturated by Δ9-desaturase to produce cis-9, trans-11 CLA.
|
| ln Vivo |
In vivo, trans-Vaccenic acid (1% w/w in diet for 8 weeks) has been shown to alleviate features of metabolic syndrome (MetS) in a rat model of obesity. It reduces total body fat, mesenteric fat, and adipocyte size, while increasing inguinal fat mass. These effects are potentially mediated by remodeling adipose tissue and attenuating ectopic lipid accumulation. Its role as a precursor to CLA also contributes to its metabolic benefits.
|
| Enzyme Assay |
In vitro non-cell enzyme/receptor binding assays for trans-Vaccenic acid are typically not performed, as it acts through cellular signaling pathways rather than direct enzyme inhibition. However, its effects on the Akt pathway can be studied in cell lysates using phospho-specific antibodies in ELISA or Western blot-based assays. Its role as a substrate for Δ9-desaturase can be studied in vitro using microsomal preparations.
|
| Cell Assay |
In vitro cell-based assays for trans-Vaccenic acid use cancer cell lines, such as nasopharyngeal carcinoma (NPC) cells. Cells are treated with the compound at various concentrations (e.g., 0-200 µM) for 24 hours. Cell viability is assessed using standard assays like MTT or CCK-8. Apoptosis is evaluated by measuring the levels of cleaved PARP and cleaved caspase-3 via Western blotting. The inhibition of Akt and Bad phosphorylation is also confirmed by Western blot.
|
| Animal Protocol |
In vivo animal studies for trans-Vaccenic acid typically use rodent models of obesity and metabolic syndrome. In a rat model, the compound is administered at 1% w/w in the diet for 8 weeks. Parameters assessed include body weight, total body fat, mesenteric fat, adipocyte size, and various metabolic markers. The compound's effects on lipid metabolism and adipose tissue remodeling are evaluated to understand its protective effects against metabolic syndrome.
|
| ADME/Pharmacokinetics |
trans-Vaccenic acid has a molecular weight of 282.46 g/mol and a molecular formula of C₁₈H₃₄O₂. It is a solid at room temperature. It is soluble in DMSO (100 mg/mL) and other organic solvents. For in vivo studies, it can be formulated in corn oil. It should be stored at 4°C, sealed, and away from moisture and light. As a fatty acid, it is absorbed and incorporated into lipid metabolism pathways.
|
| Toxicity/Toxicokinetics |
trans-Vaccenic acid is generally recognized as safe (GRAS) as a component of food. Studies in rats at a dose of 1% w/w in the diet have shown beneficial effects without significant toxicity. However, as with other fatty acids, high doses may lead to metabolic disturbances. It is not intended for therapeutic use without further development and regulatory approval.
|
| References | |
| Additional Infomation |
Trans-octadecenoic acid (ECA) is an octadecenoic acid with a double bond at position 11, which can exist in either the cis or trans configuration. It is an octadecenoic acid and a straight-chain fatty acid. It is the conjugate acid of trans-octadecenoic acid (1-). ECA is a metabolite found or produced in Escherichia coli (strains K12 and MG1655). It has been reported to exist in Brazilian mushrooms, Allamanda cathartica, and other organisms with relevant data.
trans-Vaccenic acid is a naturally occurring trans fatty acid found in ruminant fats and dairy products. It is a precursor to the beneficial conjugated linoleic acid (CLA) isomer. It has been shown to inhibit nasopharyngeal carcinoma cell growth and induce apoptosis, and to alleviate features of metabolic syndrome in animal models. It is also known as trans-11-octadecenoic acid. It is used in research to study fatty acid metabolism and cancer. |
| Molecular Formula |
C18H34O2
|
|---|---|
| Molecular Weight |
282.46136
|
| Exact Mass |
282.255
|
| CAS # |
693-72-1
|
| PubChem CID |
5281127
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
398.2±11.0 °C at 760 mmHg
|
| Melting Point |
44℃
|
| Flash Point |
295.0±14.4 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
7.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
20
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC/C=C/CCCCCCCCCC(O)=O
|
| InChi Key |
UWHZIFQPPBDJPM-BQYQJAHWSA-N
|
| InChi Code |
InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-8H,2-6,9-17H2,1H3,(H,19,20)/b8-7+
|
| Chemical Name |
(E)-octadec-11-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.85 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (177.02 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5403 mL | 17.7016 mL | 35.4032 mL | |
| 5 mM | 0.7081 mL | 3.5403 mL | 7.0806 mL | |
| 10 mM | 0.3540 mL | 1.7702 mL | 3.5403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
